Loading...
TELA Bio Q1 2025 Earnings Report
TELA Bio reported its financial results for the first quarter ended March 31, 2025, showing revenue growth and a focus on profitability.
Key Takeaways
TELA Bio delivered revenue of $18.5 million in Q1 2025, an increase of 12% year-over-year, driven by increased demand for OviTex® products and new customer acquisitions. Despite a decrease in gross margin due to inventory adjustments, the company reiterated its full-year 2025 revenue guidance.
Revenue reached $18.5 million in Q1 2025, marking a 12% increase over the prior year and 5% sequential growth.
Demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products increased, with year-over-year revenue growth of approximately 15% and 2% respectively.
The company commenced a full U.S. commercial launch of larger-sized OviTex PRS for plastic and reconstructive surgery.
TELA Bio reiterated its full year 2025 revenue guidance of $85.0 million to $88.0 million, representing 23% to 27% year-over-year growth.
Forward Guidance
TELA Bio reiterated its full year 2025 revenue guidance and expects operating expenses to remain flat compared to 2024.
Positive Outlook
- Full year 2025 revenue is projected to range from $85.0 million to $88.0 million.
- This represents a significant growth of 23% to 27% over full year 2024.
- The company aims to drive higher revenue growth throughout 2025.
- Increased operating leverage is expected.
- The company continues to drive towards profitability.
Challenges Ahead
- 2025 operating expenses are expected to be flat to 2024, which could impact profitability if revenue growth is not as strong as projected.
- The company did not provide specific guidance on net income or EPS for the full year.
- Potential macroeconomic conditions, including recessionary concerns and inflation, could impact business.
- Changes in surgical procedure volumes or frequency due to illness or other factors could affect product demand.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...